SCHEMBL24166159

SCHEMBL24166159

COCCn1c(C2CCCCC2)nc2ccc(N)cc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ BRD4 O60885 3/20 0.48
▸ ALDH1A1 P00352 4/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ ATM Q13315 2/20 0.43
▸ KDM4E B2RXH2 4/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ TSHR P16473 3/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656807 1.00 KMT2A (0.52) KMT2AMEN1BRD4ALDH1A1NPSR1
SCHEMBL24166888 0.99 MEN1 (0.51) KMT2AMEN1BRD4ALDH1A1NPSR1
SCHEMBL30656852 0.99 MEN1 (0.51) KMT2AMEN1BRD4ALDH1A1NPSR1
SCHEMBL24165968 0.91 BRD4 (0.48) KMT2AMEN1BRD4ALDH1A1ATM
SCHEMBL24165965 0.88 BRD4 (0.46) KMT2AMEN1BRD4ALDH1A1ATM
SCHEMBL26758114 0.83 MEN1 (0.49) KMT2AMEN1BRD4ALDH1A1SMN1; SMN2
SCHEMBL30426859 0.83 SYK (0.45) KMT2AMEN1BRD4ALDH1A1ATM
SCHEMBL24165959 0.83 SYK (0.45) KMT2AMEN1BRD4ALDH1A1ATM
SCHEMBL26758112 0.82 MEN1 (0.48) KMT2AMEN1BRD4ALDH1A1SMN1; SMN2
SCHEMBL30656780 0.81 BRD4 (0.48) KMT2AMEN1BRD4ALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 — — US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 — — US disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC KMT2A 3393/4885MEN1 3700/4885BRD4 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback